表紙
市場調查報告書
商品編碼
1024228

趨化素受體:現在及今後的市場機會,流行病學研究,市場動態,開發平台分析,r-NPV分析

Chemokine Receptors - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis

出版日期: | 出版商: GervanoRA Data Services LLP | 英文 253 Pages | 商品交期: 3-5個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供趨化素受體的相關調查,提供流行病學研究,市場規模和預測,活用KOL洞察的新加入企業價格策略,風險調整淨現值(RNPV)分析,開發管線洞察和基準概述,競爭情形,未滿足需求和機會等資訊。

目錄

第1章 簡介

第2章 摘要整理

第3章 趨化素受體的概要與流行病學研究

第4章 趨化素受體的市場銷售額:現在·預測(2020-2030)

第5章 開發平台(管線)的洞察和基準預測

第6章 趨化素受體競爭空間的交易活動

第7章 趨化素受體管線藥物的專利比較分析

第8章 風險調整淨現值(R-NPV)分析

第9章 競爭機會的評估

目錄
Product Code: GERPH895

GervanoRA's pipeline analysis and opportunity assessment report "Chemokine Receptors - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis" analysed and assessed Chemokine Receptors pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Chemokine Receptors drugs industry.

The report has been divided into segments like Chemokine Receptors Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Chemokine Receptors area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Chemokine Receptors drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Chemokine Receptor Type, Pipeline Analytics by Molecule Type, Pipeline Analytics by Target and Pipeline Analytics by Company Type.

The report delivers an in-depth understanding of the Chemokine Receptors historical and forecasted epidemiology based market trends Worldwide, the United States, EU9 (Poland, Russia, Switzerland, Sweden, Italy, Germany, Austria, France, and United Kingdom) and China. A detailed analytics on the Current Chemokine Receptors Market (2020) and the Forecasted Chemokine Receptors Market until the year 2030 for the regions have been provided.

Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the Emerging companies in the domain based on In-Licensing opportunities, Out-Licensing opportunities, Corporate Partnering opportunities and funding opportunities. The report even aimed to conduct the Risk-Adjusted Net Present Value (RNPV) Analysis with its Excel based r-NPV analysis model to help companies in licensing negotiations, technology valuations and pipeline asset valuation and establishing the value for licensing deal. It also aims to provide the sales potential of the drugs along with the new drugs pricing and pricing strategies.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Epidemiological Studies - Historical Trends and Probabilistic Epidemiology Forecast
  • Epidemiology Based Market Estimations - Current Market Value and Market Forecast
  • Plotting of the Anticipated Market Share for the New Entrants
  • Pricing Strategies of New Entrants Supported Through KOL Insights
  • Risk-Adjusted Net Present Value (RNPV) Analysis
  • Comparative Pipeline Insights and Benchmarking Snapshots by HSD, Geography, RoA, Molecule Target, Molecule Type
  • Unmet Needs and Opportunities
  • Comparative Patent Analytics of Chemokine Receptors Pipeline Drugs
  • Competitive Opportunity Assessments of the Active Players in the Chemokine Receptors Therapeutic Space by Partnering, Licensing and Funding Opportunities
  • Deals Activities of Chemokine Receptors Therapeutic Space

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: CHEMOKINE RECEPTORS OVERVIEW AND EPIDEMIOLOGICAL STUDIES

CHAPTER 4: CHEMOKINE RECEPTORS CURRENT MARKET VALUE AND FORECAST 2020 - 2030

CHAPTER 5: PIPELINE INSIGHTS AND BENCHMARKING OUTLOOK

CHAPTER 6: DEALS ACTIVITIES OF CHEMOKINE RECEPTORS COMPETITIVE SPACE

CHAPTER 7: COMPARATIVE PATENT ANALYTICS OF CHEMOKINE RECEPTORS PIPELINE DRUGS

CHAPTER 8: RISK-ADJUSTED NET PRESENT VALUE (R-NPV) ANALYSIS

CHAPTER 9: COMPETITIVE OPPORTUNITY ASSESSMENTS

LIST OF TABLES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: TOP 10 DEALS INVOLVING CHEMOKINE RECEPTORS RANKED BY DEAL AMOUNT IN M
  • TABLE 03: CHEMOKINE RECEPTORS COLLABORATION DEALS
  • TABLE 04: CHEMOKINE RECEPTORS FINANCING DEALS
  • TABLE 05: CHEMOKINE RECEPTORS LICENSING DEALS
  • TABLE 06: PHASE 3 CHEMOKINE RECEPTOR MOLECULES
  • TABLE 07: PHASE 2 CHEMOKINE RECEPTOR MOLECULES
  • TABLE 08: PHASE 1 CHEMOKINE RECEPTOR MOLECULES
  • TABLE 09: PRECLINICAL CHEMOKINE RECEPTOR MOLECULES
  • TABLE 10: EARLY R&D CHEMOKINE RECEPTOR BASED PIPELINE MOLECULES
  • TABLE 11: INACTIVE AND DISCONTINUED CHEMOKINE RECEPTOR BASE PIPELINE MOLECULES
  • TABLE 12: ADVANCED STAGE CHEMOKINE RECEPTOR MOLECULES AND THEIR APPROVAL REGIONS
  • TABLE 13: LIST OF COMPANIES DEVELOPING PIPELINE MOLECULES FOR ONCOLOGY THERAPEUTIC AREA
  • TABLE 14: LIST OF COMPANIES DEVELOPING PIPELINE MOLECULES FOR ONCOLOGY INDICATIONS
  • TABLE 15: CHEMOKINE RECEPTOR PIPELINE ANALYSIS BY TARGET
  • TABLE 16: CHEMOKINE RECEPTOR PIPELINE ANALYSIS BY RECEPTOR TYPE
  • TABLE 17: CHEMOKINE RECEPTOR PIPELINE ANALYSIS BY COMPANY TYPE
  • TABLE 18: ESTIMATED APPROVAL TIMELINES OF PRE-REGISTRATION AND PHASE 3 MOLECULES (US & EX-US)

LIST OF FIGURES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • FIGURE 01: KEY EVENTS IN THE COMPETITIVE SPACE
  • FIGURE 02: TYPICAL REPESENTATION OF CHEMOKINE RECEPTOR STRUCTURE
  • FIGURE 03: CXCR CHEMOKINE RECEPTOR
  • FIGURE 04: CCR CHEMOKINE RECEPTOR
  • FIGURE 05: XCR CHEMOKINE RECEPTOR
  • FIGURE 06: CX3CR CHEMOKINE RECEPTOR
  • FIGURE 07: ROLE OF CHEMOKINE AND CHEMOKINE RECEPTORS
  • FIGURE 08: CHEMOKINE RECEPTORS DEALS BY DEAL TYPE
  • FIGURE 09: CHEMOKINE RECEPTOR DEALS BY ANNUAL FREQUENCY
  • FIGURE 10: CHEMOKINE RECEPTOR DEALS BY DISEASE AREA
  • FIGURE 11: CHEMOKINE RECEPTOR PIPELINE MOLECULES BY STAGE OF DEVELOPMENT
  • FIGURE 12: CHEMOKINE RECEPTOR PIPELINE ANALYSIS BY GEOGRAPHY
  • FIGURE 13: CHEMOKINE RECEPTOR PIPELINE ANALYSIS BY ROA
  • FIGURE 14: CHEMOKINE RECEPTOR BASED PIPELINE ANALYSIS BY THERAPEUTIC AREA
  • FIGURE 15: CHEMOKINE RECEPTOR PIPELINE ANALYSIS BY COMPANY TYPE